The report on European antihypertensive medicine sales reveals that in 2024, Austria leads with 50.9 million Euros, followed by Latvia and Portugal both at 2.8 million Euros, Estonia at 1.3 million Euros, and Luxembourg bringing up the rear at 0.7 million Euros. Year-on-year variations from 2023 highlight trends: Austria saw an increase of 2.22%, Latvia a decline of 6.41%, Portugal a minimal decrease of 0.7%, while Estonia and Luxembourg experienced increases of 5.39% and 6.96%, respectively. Over the past five years, these percentages depict a substantial annual growth or contraction, shedding light on dynamic market patterns.
Future trends to watch for include potential regulatory changes, economic shifts, and healthcare policy reforms that could impact the market. Additionally, the aging population and technological advancements in healthcare are likely to influence the demand and sales of antihypertensive medicines across Europe.
Top countries in Antihypertensive Medicine Sales by Country
| # | 5 Countries | Million Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Austria | 50.9 | 2023 | +0.99% | +2.22% | View data |
| 2 | 2 Latvia | 2.8 | 2023 | -6.67% | -6.41% | View data |
| 3 | 3 Portugal | 2.8 | 2023 | 0% | -0.7% | View data |
| 4 | 4 Estonia | 1.3 | 2023 | 0% | +5.39% | View data |
| 5 | 5 Luxembourg | 0.7 | 2023 | 0% | +6.96% | View data |
